Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207216 | 0.87 | GAA (0.47) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL30849463 | 0.87 | GAA (0.47) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL30849442 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL15747830 | 0.83 | TNF (0.46) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27896846 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL31439350 | 0.82 | EGFR (0.46) | EGFRERBB2 | |
| SCHEMBL31439375 | 0.82 | LMNA (0.38) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12482516 | 0.81 | PIK3CA (0.46) | MEN1KMT2AEGFRERBB2 | |
| SCHEMBL27915545 | 0.81 | LMNA (0.48) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16054942 | 0.80 | TNF (0.37) | MEN1KMT2AALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062046-B2 | Substituted imidazoquinoline derivatives as kinase inhibitors | Piramal Enterprises Limited (IN) | 2015-06-23 | — | — | US | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| CN-103108873-A | Substituted imidazoquinoline derivatives as kinase inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-05-15 | — | — | CN | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | MEN1 2898/4885PABPC1 3776/4885KMT2A 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.